Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East

Annals of Hematology

Volumn 86, Issue 12, 2007, Pages 887-895

  Siraj, Abdul K ^a   Ibrahim, Muna ^a   Al Rasheed, Maha ^a   Bu, Rong ^a   Bavi, Prashant ^a   Jehan, Zeenath ^a   Abubaker, Jehad ^a   Murad, Walid ^a   Al Dayel, Fouad ^a   Ezzat, Adnan ^a   El Solh, Hassan ^a   Uddin, Shahab ^a   Al Kuraya, Khawla ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Diffuse large B cell lymphoma; FHIT; Methylation; MGMT; MTHFR

Indexed keywords

ACID ANHYDRIDE HYDROLASE; DNA METHYLTRANSFERASE; FRAGILE HISTIDINE TRIAD PROTEIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROMOTER REGION; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ACID ANHYDRIDE HYDROLASES; ADULT; BASE SEQUENCE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SAUDI ARABIA; TUMOR SUPPRESSOR PROTEINS;

EID: 40949141132     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-007-0350-2     Document Type: Article

References (43)

1. Anonymous (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918
2. Bazarbashi S, De Vol E, Young S, Al-Eid H, Arteh S (2004) Cancer incidence report Saudi Arabia 1999-2000. National Cancer Registry, Saudi Arabia
3. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282
4. Hartge P, Wang SS (2004) Overview of the etiology and epidemiology of lymphoma. In:Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL (eds) Non-Hodgkin's lymphomas. Lippincott Williams and Wilkins, Philadelphia, pp 711-727
5. Chiu BC, Weisenburger DD (2003) An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 4:161-168
6. Blair A, Zahm SH (1995) Agricultural exposures and cancer. Environ Health Perspect 103:205-208
7. Dich J, Zahm SH, Hanberg A, Adami HO (1997) Pesticides and cancer. Cancer Causes Control 8:420-443
8. O'Connor SR, Farmer PB, Lauder I (1999) Benzene and non- Hodgkin's lymphoma. J Pathol 189:448-453
9. Garte S, Gaspari L, Alexandrie AK et al (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomark Prev 10:1239-1248
10. Zhu K, Levine RS, Brann EA, Gu Y, Caplan LS, Hall I, Baum MK (2001) Risk factors for non-Hodgkin's lymphoma according to family history of haematolymphoproliferative malignancies. Int J Epidemiol 30:818-824
11. Chiu BC, Weisenburger DD, Zahm SH, Cantor KP, Gapstur SM, Holmes F, Burmeister LF, Blair A (2004) Agricultural pesticide use, familial cancer, and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomark Prev 13:525-531
12. Sekine I, Saijo N (2001) Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 12:1515-1525
13. Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99:754-758
14. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658
15. Relling MV, Dervieux T (1996) Pharmacogenetics and cancer therapy. Nat Rev Cancer 1:99-108
16. Nebert DW, Mckinnon RA, Puga A (1996) Human drugmetabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280
17. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, Sinnett D (2002) Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 8:802-810
18. Robien K, Ulrich CM (2003) 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 157:571-582, Review
19. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100:3832-3834
20. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Tajima K (2003) Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 88:159-166
21. Matsuo K, Suzuki R, Hamajima N et al (2001) Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 97:3205-3209
22. Al-Kuraya K, Narayanappa R, Siraj AK, Al-Dayel F, Ezzat A, Solh HE, Al-Jommah N, Sauter G, Simon R (2006) High frequency and strong prognostic relevance of O(6)-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. Hum Pathol 37:742-748
23. Al Kuraya K, Siraj AK, Bavi P, Al-Jomah N, El-Solh H, Ezzat A, Al-Dayel F, Belgaumi A, Al-Kofide A, Sabbah R, Sheikh S, Amr S, Simon R, Sauter G (2006) High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Mod Pathol 19:1124-1129
24. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG (2002) Hypermethylation of the DNA repair gene O (6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26-32
25. Chen P, Yang M et al (2004) Decreased FHIT protein expression correlates with a worse prognosis in patients with diffuse large B cell lymphoma. Oncol Rep 11:349-356
26. Kameoka Y, Tagawa H, Tsuzuki S, Karnan S, Ota A, Suguro M, Suzuki R, Yamaguchi M, Morishima Y, Nakamura S, Seto M (2004) Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 23:9148-54
27. Friso S, Choi SW, Girelli D,Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Corrocher R, Selhub J (2002) Acommonmutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99:5606-5611
28. Stern LL, Mason JB, Selhub J, Choi SW (2000) Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomark Prev 9:849-853
29. Toffoli G, Cecchin E (2003) Pharmacogenetics of stomach cancer. Tumori Suppl 2:S19-S22
30. Chiusolo P, Reddiconto G, Casorelli I et al (2002) Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13:1915-1918
31. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ (2000) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 6:744-745
32. Bu R, Gutierrez MI, Al-Rasheed M, Belgaumi A, Bhatia K (2004) Variable drug metabolism genes in Arab population. Pharmacogenomics J 4:260-266
33. Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A (2003) Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers 18:218-221
34. Clarizia AD, Bastos-Rodrigues L, Pena HB, Anacleto C, Rossi B, Soares FA, Lopes A, Rocha JC, Caballero O, Camargo A, Simpson AJ, Pena SD (2006) Relationship of the methylenetetrahydrofolate reductase C677T polymorphism with microsatellite instability and promoter hypermethylation in sporadic colorectal cancer. Genet Mol Res 5(2):315-322
35. Matsuo K, Hamajima N, Suzuki R, Ogura M, Kagami Y, Taji H, Yasue T, Mueller NE, Nakamura S, Seto M, Morishima Y, Tajima K (2004) Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol 77:351-357
36. Frosst P, Blom HJ,Milos R, Goyette P, Sheppard CA,Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113
37. Skibola CF, Forrest MS, Coppede F, Agana L, Hubbard A, Smith MT, Bracci PM, Holly EA (2004) Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 104:2155-2162
38. Lightfoot TJ, Skibola CF, Willett EV, Skibola DR, Allan JM, Coppede F, Adamson PJ, Morgan GJ, Roman E, Smith MT (2005) Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomark Prev 14:2999-3003
39. Habib EE, Aziz M, KotbM(2005) Genetic polymorphism of folate and methionine metabolizing enzymes and their susceptibility to malignant lymphoma. J Egypt Natl Cancer Inst 17:184-192
40. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A (2003) Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 120:1051-1054
41. Lim U, Wang SS, Hartge P, Cozen W, Kelemen LE, Chanock S, Davis S, Blair A, Schenk M, Rothman N, Lan Q (2006) Genenutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study. Blood 109:3050-3059
42. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML (1999) The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 6:359-365
43. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:3574-3581